Shares of EyeGate Pharmaceuticals (NASDAQ: EYEG) are rallying premarket on Monday after the company revealed it will acquire Panoptes Pharma, a privately-held clinical-stage biotech company.
EyeGate said the acquisition will transform its pipeline with the addition of PP-001, a “next-generation, non-steroidal, immuno-modulatory, small-molecule inhibitor of Dihydroorotate Dehydrogenase (DHODH) with potential best-in-class picomolar potency.”
EyeGate will pay $4 million for Panoptes, which will consist of EyeGate common stock, preferred stock and cash. A further $1.5 million in EyeGate common stock will be issued after 18 months, subject to certain conditions.
Interested in investing after today’s move?
XTB gives investors access to thousands of UK and international stocks,
including fractional shares from just £1.
Explore stocks with XTB →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to invest in the stocks making the news?
Go from following the market to investing in it, with access to thousands
of stocks across major UK and international markets.
See available stocks →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Own the stocks you’re reading about
Invest in real shares across the UK, US and other major global markets
through XTB, all from one investment account.
Explore XTB shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
You don’t need to buy a whole share
Fractional shares let you invest from just £1, giving you more control
over how much you put into individual companies.
Explore fractional shares →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
Want to see how XTB works first?
Explore the platform with an XTB demo account before deciding whether
you want to invest with real money.
Try the XTB demo →
Your capital is at risk. The value of your investments may go up or down. Past performance is not a reliable indicator of future performance.
The transaction also includes two cash or share earn-out provisions, each for an additional payment of up to $4,750,000 contingent upon 1) the enrollment and randomisation of a first patient into the first Phase III pivotal study of any Panoptes ophthalmic product with the FDA, and 2) approval of a New Drug Application by the FDA for any Panoptes ophthalmic product.
“The acquisition of Panoptes propels the EyeGate pipeline forward to include a de-risked clinical-stage candidate with broad potential across a diverse range of ocular, autoimmune and neurological indications,” said Stephen From, CEO of EyeGate.
The news has resulted in a rally for EyeGate’s share price. It is currently up 85.87% premarket at $6.60 following Friday’s close at $3.57.
